Fusidic acid is active against a wide range of gram-positive organisms, particularly Staphylococci. Other species against which fusidic acid exerts high clinical activity include Streptococci, Pneumococci, Neisseria, Haemophilus, Moraxella and Corynebacteria.
No cross-resistance with fusidic acid and other clinically available antibiotics is shown, and fusidic acid is stable to bacterial β-lactamases.
The sustained-release formulation of Fucithalmic ensures prolonged contact with the conjunctival sac. Twice-daily application provides sufficient concentrations of fusidic acid in all relevant tissues of the eye. It penetrates well into the aqueous humour.
Fusidic acid is generally atoxic, and experience with its dermatological use shows a very low allergenic potential. No cross-allergy with other antibiotics is shown by patients treated with fusidic acid.
Bacterial infections of the eye caused by susceptible organisms in conjunctivitis, blepharitis, sty, keratitis and dacryocystitis. Prophylaxis in ophthalmic surgery and in connection with removal of foreign bodies.
Instil 1 drop in the conjunctival sac every 12 hrs. Treatment should be continued for 2 days after the eye appears normal. On the 1st day of the treatment, Fucithalmic may be applied more frequently eg, 1 drop every 4 hrs.
Surgical Prophylaxis: 1 drop every 12 hrs, 24-48 hrs before operation.
Allergy to any of the constituents.
Fucithalmic should not be applied while patients are wearing contact lenses. Such patients should be advised to wear glasses during the treatment.
Transient stinging after application has been reported.
Cross-allergy between fusidic acid and other antibiotics has not been reported.
S01AA13 - fusidic acid ; Belongs to the class of antibiotics. Used in the treatment of eye infections.